[
    [
        {
            "time": "2018-03-15",
            "original_text": "Cheap Dividend Aristocrats to Buy Now",
            "features": {
                "keywords": [
                    "Cheap",
                    "Dividend",
                    "Aristocrats",
                    "Buy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Cheap Dividend Aristocrats to Buy Now",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-06-20",
            "original_text": "AbbVie Is Angling To Rival Biogen In Alzheimer's — But Is AbbVie Stock A Buy?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rival",
                    "Biogen",
                    "Alzheimer's",
                    "Stock",
                    "Buy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Is Angling To Rival Biogen In Alzheimer's — But Is AbbVie Stock A Buy?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-04-10",
            "original_text": "AbbVie Receives a Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for VENCLEXTA® (venetoclax) in Combination with azacitidine for Acute Myeloid Leukemia (AML) Patients",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Positive",
                    "Reimbursement",
                    "Recommendation",
                    "VENCLEXTA",
                    "AML",
                    "Patients"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Receives a Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for VENCLEXTA® (venetoclax) in Combination with azacitidine for Acute Myeloid Leukemia (AML) Patients",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-09-15",
            "original_text": "Best Dividend Stocks September 2021",
            "features": {
                "keywords": [
                    "Best",
                    "Dividend",
                    "Stocks",
                    "September",
                    "2021"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Best Dividend Stocks September 2021",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "2022-02-10",
            "original_text": "3 Pharma Stocks to Buy With Juicy Dividends",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stocks",
                    "Buy",
                    "Juicy",
                    "Dividends"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "3 Pharma Stocks to Buy With Juicy Dividends",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]